167 related articles for article (PubMed ID: 20501761)
1. Anti-MUC1 antibodies and ovarian cancer risk: prospective data from the Nurses' Health Studies.
Pinheiro SP; Hankinson SE; Tworoger SS; Rosner BA; McKolanis JR; Finn OJ; Cramer DW
Cancer Epidemiol Biomarkers Prev; 2010 Jun; 19(6):1595-601. PubMed ID: 20501761
[TBL] [Abstract][Full Text] [Related]
2. Antibodies reactive with the protein core of MUC1 mucin are present in ovarian cancer patients and healthy women.
Richards ER; Devine PL; Quin RJ; Fontenot JD; Ward BG; McGuckin MA
Cancer Immunol Immunother; 1998 Jul; 46(5):245-52. PubMed ID: 9690452
[TBL] [Abstract][Full Text] [Related]
3. Conditions associated with antibodies against the tumor-associated antigen MUC1 and their relationship to risk for ovarian cancer.
Cramer DW; Titus-Ernstoff L; McKolanis JR; Welch WR; Vitonis AF; Berkowitz RS; Finn OJ
Cancer Epidemiol Biomarkers Prev; 2005 May; 14(5):1125-31. PubMed ID: 15894662
[TBL] [Abstract][Full Text] [Related]
4. Incessant ovulation, mucin 1 immunity, and risk for ovarian cancer.
Terry KL; Titus-Ernstoff L; McKolanis JR; Welch WR; Finn OJ; Cramer DW
Cancer Epidemiol Biomarkers Prev; 2007 Jan; 16(1):30-5. PubMed ID: 17220329
[TBL] [Abstract][Full Text] [Related]
5. Soluble MUC1 and serum MUC1-specific antibodies are potential prognostic biomarkers for platinum-resistant ovarian cancer.
Budiu RA; Mantia-Smaldone G; Elishaev E; Chu T; Thaller J; McCabe K; Lenzner D; Edwards RP; Vlad AM
Cancer Immunol Immunother; 2011 Jul; 60(7):975-84. PubMed ID: 21461842
[TBL] [Abstract][Full Text] [Related]
6. Mumps and ovarian cancer: modern interpretation of an historic association.
Cramer DW; Vitonis AF; Pinheiro SP; McKolanis JR; Fichorova RN; Brown KE; Hatchette TF; Finn OJ
Cancer Causes Control; 2010 Aug; 21(8):1193-201. PubMed ID: 20559706
[TBL] [Abstract][Full Text] [Related]
7. Puerperal mastitis: a reproductive event of importance affecting anti-mucin antibody levels and ovarian cancer risk.
Cramer DW; Williams K; Vitonis AF; Yamamoto HS; Stuebe A; Welch WR; Titus L; Fichorova RN
Cancer Causes Control; 2013 Nov; 24(11):1911-23. PubMed ID: 23925696
[TBL] [Abstract][Full Text] [Related]
8. Cellular and humoral immune responses to MUC1 mucin and tandem-repeat peptides in ovarian cancer patients and controls.
Snijdewint FG; von Mensdorff-Pouilly S; Karuntu-Wanamarta AH; Verstraeten AA; van Zanten-Przybysz I; Hummel P; Nijman HW; Kenemans P; Hilgers J
Cancer Immunol Immunother; 1999 Apr; 48(1):47-55. PubMed ID: 10235488
[TBL] [Abstract][Full Text] [Related]
9. Humoral immune responses to MUC1 in women with a BRCA1 or BRCA2 mutation.
Hermsen BB; Verheijen RH; Menko FH; Gille JJ; van Uffelen K; Blankenstein MA; Meijer S; van Diest PJ; Kenemans P; von Mensdorff-Pouilly S
Eur J Cancer; 2007 Jul; 43(10):1556-63. PubMed ID: 17532207
[TBL] [Abstract][Full Text] [Related]
10. Autoantibodies to MUC1 glycopeptides cannot be used as a screening assay for early detection of breast, ovarian, lung or pancreatic cancer.
Burford B; Gentry-Maharaj A; Graham R; Allen D; Pedersen JW; Nudelman AS; Blixt O; Fourkala EO; Bueti D; Dawnay A; Ford J; Desai R; David L; Trinder P; Acres B; Schwientek T; Gammerman A; Reis CA; Silva L; Osório H; Hallett R; Wandall HH; Mandel U; Hollingsworth MA; Jacobs I; Fentiman I; Clausen H; Taylor-Papadimitriou J; Menon U; Burchell JM
Br J Cancer; 2013 May; 108(10):2045-55. PubMed ID: 23652307
[TBL] [Abstract][Full Text] [Related]
11. Cancer-associated autoantibodies to MUC1 and MUC4--a blinded case–control study of colorectal cancer in UK collaborative trial of ovarian cancer screening.
Pedersen JW; Gentry-Maharaj A; Nøstdal A; Fourkala EO; Dawnay A; Burnell M; Zaikin A; Burchell J; Papadimitriou JT; Clausen H; Jacobs I; Menon U; Wandall HH
Int J Cancer; 2014 May; 134(9):2180-88. PubMed ID: 24122770
[TBL] [Abstract][Full Text] [Related]
12. Circulating anti-MUC1 IgG antibodies as a favorable prognostic factor for pancreatic cancer.
Hamanaka Y; Suehiro Y; Fukui M; Shikichi K; Imai K; Hinoda Y
Int J Cancer; 2003 Jan; 103(1):97-100. PubMed ID: 12455059
[TBL] [Abstract][Full Text] [Related]
13. Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of incident ovarian cancer.
Tworoger SS; Lee IM; Buring JE; Rosner B; Hollis BW; Hankinson SE
Cancer Epidemiol Biomarkers Prev; 2007 Apr; 16(4):783-8. PubMed ID: 17416771
[TBL] [Abstract][Full Text] [Related]
14. Determination of MUC1 in sera of ovarian cancer patients and in sera of patients with benign changes of the ovaries with CA15-3, CA27.29, and PankoMab.
Jeschke U; Wiest I; Schumacher AL; Kupka M; Rack B; Stahn R; Karsten U; Mayr D; Friese K; Dian D
Anticancer Res; 2012 May; 32(5):2185-9. PubMed ID: 22593508
[TBL] [Abstract][Full Text] [Related]
15. Humoral immune response to abnormal MUC1 in subjects with colorectal adenoma and cancer.
Silk AW; Schoen RE; Potter DM; Finn OJ
Mol Immunol; 2009 Nov; 47(1):52-6. PubMed ID: 19217667
[TBL] [Abstract][Full Text] [Related]
16. Induction of IgG antibodies to MUC1 and survival in patients with epithelial ovarian cancer.
Oei AL; Moreno M; Verheijen RH; Sweep FC; Thomas CM; Massuger LF; von Mensdorff-Pouilly S
Int J Cancer; 2008 Oct; 123(8):1848-53. PubMed ID: 18661524
[TBL] [Abstract][Full Text] [Related]
17. Plasma androgen concentrations and risk of incident ovarian cancer.
Tworoger SS; Lee IM; Buring JE; Hankinson SE
Am J Epidemiol; 2008 Jan; 167(2):211-8. PubMed ID: 17982156
[TBL] [Abstract][Full Text] [Related]
18. Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin.
von Mensdorff-Pouilly S; Verstraeten AA; Kenemans P; Snijdewint FG; Kok A; Van Kamp GJ; Paul MA; Van Diest PJ; Meijer S; Hilgers J
J Clin Oncol; 2000 Feb; 18(3):574-83. PubMed ID: 10653872
[TBL] [Abstract][Full Text] [Related]
19. Risk factors for epithelial ovarian cancer in Beijing, China.
Chen Y; Wu PC; Lang JH; Ge WJ; Hartge P; Brinton LA
Int J Epidemiol; 1992 Feb; 21(1):23-9. PubMed ID: 1544753
[TBL] [Abstract][Full Text] [Related]
20. Immunobiology of human mucin 1 in a preclinical ovarian tumor model.
Budiu RA; Elishaev E; Brozick J; Lee M; Edwards RP; Kalinski P; Vlad AM
Oncogene; 2013 Aug; 32(32):3664-75. PubMed ID: 22964632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]